

Quotient Ltd  
Form 10-Q  
October 31, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 001-36415

QUOTIENT LIMITED

(Exact name of registrant as specified in its charter)

Jersey, Channel Islands  
(State or other jurisdiction of  
incorporation or organization)

Not Applicable  
(I.R.S. Employer  
Identification No.)

B1, Business Park Terre Bonne,  
Route de Crassier 13,

Not Applicable

Edgar Filing: Quotient Ltd - Form 10-Q

1262 Eysins, Switzerland  
(Address of principal executive offices) (Zip Code)

011-41-22-716-9800

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

(Do not check if a small reporting company) Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

As of October 30, 2017 there were 45,559,214 Ordinary Shares, nil par value, of Quotient Limited outstanding.



TABLE OF CONTENTS

	Page
<u>PART I – FINANCIAL INFORMATION</u>	3
<u>Item 1. Financial Statements</u>	3
<u>Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	18
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	30
<u>Item 4. Controls and Procedures</u>	31
<u>PART II – OTHER INFORMATION</u>	31
<u>Item 1. Legal Proceedings</u>	31
<u>Item 1A. Risk Factors</u>	31
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	31
<u>Item 3. Defaults Upon Senior Securities</u>	31
<u>Item 4. Mine Safety Disclosures</u>	31
<u>Item 5. Other Information</u>	31
<u>Item 6. Exhibits</u>	31
<u>Signatures</u>	33



Cautionary note regarding forward-looking statements

This Quarterly Report on Form 10-Q, and exhibits thereto, contains estimates, predictions, opinions, projections and other statements that may be interpreted as “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part I, Item 2: “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and are also contained elsewhere in this Quarterly Report. Forward-looking statements can be identified by words such as “strategy,” “objective,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate,” “might,” “design” and other similar expressions, although not all forward-looking statements contain these identifying words. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain, and are subject to numerous known and unknown risks and uncertainties.

Forward-looking statements include statements about:

- the development, regulatory approval and commercialization of MosaiQ™;
- the design of blood grouping and disease screening capabilities of MosaiQ and the benefits of MosaiQ for both customers and patients;
- future demand for and customer adoption of MosaiQ, the factors that we believe will drive such demand and our ability to address such demand;
- our expected profit margins for MosaiQ;
- the size of the market for MosaiQ ;
- the regulation of MosaiQ by the U.S. Food and Drug Administration, or the FDA, or other regulatory bodies, or any unanticipated regulatory changes or scrutiny by such regulators;
- future plans for our conventional reagent products;
- the status of our future relationships with customers, suppliers, and regulators relating to our conventional reagent products;
- future demand for our conventional reagent products and our ability to meet such demand;
- our ability to manage the risks associated with international operations;
- anticipated changes, trends and challenges in our business and the transfusion diagnostics market;
- the effects of competition;
- the expected outcome or impact of litigation;
- our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;
- our anticipated cash needs and our expected sources of funding, including the achievement of product development milestones and proceeds from exercises of our outstanding warrants, and our estimates regarding our capital requirements and capital expenditures; and
- our plans for executive and director compensation for the future.

You should also refer to the various factors identified in this and other reports filed by us with the Securities and Exchange Commission, including but not limited to those discussed in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended March 31, 2017, for a discussion of other important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report will prove to be accurate. Further, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this Quarterly Report represent our views only as of the date of this Quarterly

Edgar Filing: Quotient Ltd - Form 10-Q

Report. Subsequent events and developments may cause our views to change. While we may elect to update these forward-looking statements at some point in the future, we undertake no obligation to publicly update any forward-looking statements, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report.

- 1 -

---

Where you can find more information

We file annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission. You can inspect, read and copy these reports, proxy statements and other information at the Securities and Exchange Commission's Public Reference Room, which is located at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information regarding the operation of the Securities and Exchange Commission's Public Reference Room by calling the Securities and Exchange Commission at 1-800-SEC-0330. The Securities and Exchange Commission also maintains a website at [www.sec.gov](http://www.sec.gov) that makes available reports, proxy statements and other information regarding issuers that file electronically.

We make available free of charge at [www.quotientbd.com](http://www.quotientbd.com) (in the "Investors" section) copies of materials we file with, or furnish to, the Securities and Exchange Commission. By referring to our corporate website, [www.quotientbd.com](http://www.quotientbd.com), we do not incorporate any such website or its contents into this Quarterly Report on Form 10-Q.



## PART I – FINANCIAL INFORMATION

## Item 1. Financial Statements

## CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

(Expressed in thousands of U.S. Dollars — except for share data and per share data)

	September 30, 2017	March 31, 2017
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$9,131	\$4,754
Short-term investments	10,686	16,057
Trade accounts receivable, net	2,458	2,556
Inventories	15,223	13,636
Prepaid expenses and other current assets	3,941	3,629
Total current assets	41,439	40,632
Cash reserve account	5,040	5,040
Property and equipment, net	74,891	63,530
Intangible assets, net	847	769
Total assets	\$122,217	\$109,971
<b>LIABILITIES AND SHAREHOLDERS' DEFICIT</b>		
Current liabilities:		
Accounts payable	\$7,484	\$10,782
Accrued compensation and benefits	3,131	3,641
Accrued expenses and other current liabilities	17,864	13,509
Current portion of lease incentive	437	422
Current portion of capital lease obligation	1,472	1,374
Total current liabilities	30,388	29,728
Long-term debt	83,586	80,704
Lease incentive, less current portion	655	844
Capital lease obligation, less current portion	439	174
Defined benefit pension plan obligation	5,727	5,337
7% Cumulative redeemable preference shares	17,800	17,275
Total liabilities	138,595	134,062
Commitments and contingencies	—	—
Shareholders' deficit		
Ordinary shares (nil par value) 37,694,531 and 29,567,698 issued and outstanding at		
September 30, 2017 and March 31, 2017 respectively	217,883	172,617
Additional paid in capital	18,357	15,885
Accumulated other comprehensive loss	(17,388 )	(19,292 )
Accumulated deficit	(235,230)	(193,301)
Total shareholders' deficit	(16,378 )	(24,091 )

Total liabilities and shareholders' deficit	\$ 122,217	\$ 109,971
---	------------	------------

The accompanying notes form an integral part of these consolidated financial statements.

- 3 -

---

## CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited)

(Expressed in thousands of U.S. Dollars — except for share data and per share data)

	Quarter ended September 30,		Six months ended September 30,	
	2017	2016	2017	2016
<b>Revenue:</b>				
Product sales	\$5,910	\$4,844	\$12,136	\$10,561
Other revenues	—	1,300	600	1,300
Total revenue	5,910	6,144	12,736	11,861
Cost of revenue	(2,786 )	(2,761 )	(5,618 )	(5,852 )
Gross profit	3,124	3,383	7,118	6,009
<b>Operating expenses:</b>				
Sales and marketing	(1,869 )	(1,273 )	(3,551 )	(2,530 )
Research and development, net of government grants	(13,341 )	(14,495 )	(26,014 )	(26,296 )
<b>General and administrative expense:</b>				
<b>Compensation expense in respect of share options and</b>				
management equity incentives	(1,187 )	(1,083 )	(2,472 )	(1,981 )
Other general and administrative expenses	(4,787 )	(4,043 )	(10,047 )	(9,091 )
Total general and administrative expense	(5,974 )	(5,126 )	(12,519 )	(11,072 )
Total operating expense	(21,184 )	(20,894 )	(42,084 )	(39,898 )
Operating loss	(18,060 )	(17,511 )	(34,966 )	(33,889 )
<b>Other income (expense):</b>				
Interest expense, net	(4,197 )	(1,213 )	(8,407 )	(2,384 )
Other, net	565	1,366	1,444	2,680
Other income (expense), net	(3,632 )	153	(6,963 )	296
Loss before income taxes	(21,692 )	(17,358 )	(41,929 )	(33,593 )
Provision for income taxes	—	—	—	—
Net loss	\$(21,692 )	\$(17,358 )	\$(41,929 )	\$(33,593 )
<b>Other comprehensive income (loss):</b>				
<b>Change in fair value of effective portion of foreign</b>				
<b>currency cash flow</b>				
hedges	\$128	\$29	\$473	\$(234 )
Change in unrealized gain on short-term investments	(6 )	—	32	—
Foreign currency gain (loss)	(504 )	(594 )	1,312	(3,903 )
Provision for pension benefit obligation	44	46	87	87
Other comprehensive income (loss), net	(338 )	(519 )	1,904	(4,050 )
Comprehensive loss	\$(22,030 )	\$(17,877 )	\$(40,025 )	\$(37,643 )
<b>Net loss available to ordinary shareholders - basic and</b>				
<b>diluted</b>				
	\$(21,692 )	\$(17,358 )	\$(41,929 )	\$(33,593 )
Loss per share - basic and diluted	\$(0.58 )	\$(0.62 )	\$(1.13 )	\$(1.25 )
Weighted-average shares outstanding - basic and diluted	37,657,409	28,123,334	37,223,957	26,774,378

The accompanying notes form an integral part of these consolidated financial statements.

- 4 -

---

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)  
(unaudited)

(Expressed in thousands of U.S. Dollars — except for share data)

	Accumulated					Total Shareholders' Equity (Deficit)
	Ordinary shares Shares	Amount	Additional paid in capital	Other Comprehensive Loss	Accumulated Deficit	
March 31, 2017	29,567,698	\$172,617	\$ 15,885	\$ (19,292 )	\$ (193,301 )	\$ (24,091 )
Issue of Shares , net of Issue Costs of \$243	8,050,000	45,159	—	—	—	45,159
Issue of shares upon exercise of incentive						
share options and vesting of RSUs	76,833	107	—	—	—	107
Net loss	—	—	—	—	(41,929 )	(41,929 )
Change in the fair value of the effective						
portion of foreign currency cash						
flow hedges	—	—	—	473	—	473
Unrealized gain on short-term investments	—	—	—	32	—	32
Foreign currency gain (loss) on: Long-term investment nature intra-	—	—	—	—	—	—
entity balances	—	—	—	(4,789 )	—	(4,789 )
Retranslation of foreign entities	—	—	—	6,101	—	6,101
Provision for pension benefit obligation	—	—	—	87	—	87
Other comprehensive loss	—	—	—	1,904	—	1,904
Stock-based compensation	—	—	2,472	—	—	2,472
September 30, 2017	37,694,531	\$217,883	\$ 18,357	\$ (17,388 )	\$ (235,230 )	\$ (16,378 )

The accompanying notes form an integral part of these consolidated financial statements.

## CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

(Expressed in thousands of U.S. Dollars)

	Six months ended	
	September 30, 2017	2016
<b>OPERATING ACTIVITIES:</b>		
Net loss	\$(41,929)	\$(33,593)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Depreciation and amortization	5,081	4,641
Share-based compensation	2,472	1,981
Amortization of lease incentive	(215 )	(217 )
Swiss pension obligation	329	344
Amortization of deferred debt issue costs	2,882	506
Accrued preference share dividends	525	525
Net change in assets and liabilities:		
Trade accounts receivable, net	231	(1,870 )
Inventories	(1,065 )	(1,333 )
Accounts payable and accrued liabilities	(540 )	1,614
Accrued compensation and benefits	(560 )	10
Other assets	197	(1,629 )
Net cash used in operating activities	(32,592)	(29,021)
<b>INVESTING ACTIVITIES:</b>		
Increase in short-term investments	(43,000)	—
Realization of short-term investments	48,402	—
Purchase of property and equipment	(12,261)	(9,427 )
Purchase of intangible assets	(68 )	(65 )
Net cash used in investing activities	(6,927 )	(9,492 )
<b>FINANCING ACTIVITIES:</b>		
Repayment of finance leases	(56 )	(81 )
Proceeds from issuance of ordinary shares	45,266	16,371
Net cash generated from financing activities	45,210	16,290
Effect of exchange rate fluctuations on cash and cash equivalents	(1,314 )	(2,878 )
Change in cash and cash equivalents	4,377	(25,101)
Beginning cash and cash equivalents	4,754	44,100
Ending cash and cash equivalents	\$9,131	\$18,999
<b>Supplemental cash flow disclosures:</b>		
Income taxes paid	\$—	\$—
Interest paid	\$5,068	\$2,391

The accompanying notes form an integral part of these consolidated financial statements.



## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in thousands of U.S. Dollars — except for share data and per share data, unless otherwise stated)

### Note 1. Description of Business and Basis of Presentation

#### Description of Business

The principal activity of Quotient Limited (the “Company”) and its subsidiaries (the “Group”) is the development, manufacture and sale of products for the global transfusion diagnostics market. Products manufactured by the Group are sold to hospitals, blood banking operations and other diagnostics companies worldwide.

#### Basis of Presentation

The condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and are unaudited. In accordance with those rules and regulations, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States (“GAAP”) for complete financial statements.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) considered necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented. The March 31, 2017 balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. The financial statements should be read in conjunction with the audited consolidated financial statements at and for the year ended March 31, 2017 included in the Company’s Annual Report on Form 10-K for the year then ended. The results of operations for the six month period ended September 30, 2017 are not necessarily indicative of the results of operations that may be expected for the year ending March 31, 2018 and any future period.

The Company has incurred net losses and negative cash flows from operations in each year since it commenced operations in 2007 and had an accumulated deficit of \$235.2 million as of September 30, 2017. At September 30, 2017, the Company had available cash holdings and short-term investments of \$19.5 million. The Company has expenditure plans over the next twelve months that exceed its current cash and short-term investment balances, raising substantial doubt about its ability to continue as a going concern. The Company expects to fund its operations in the near-term, including the continued development of MosaiQ through successful field trial completion to commercialization, from a combination of funding sources, including through the use of existing cash and short-term investment balances, the issuance of new equity, debt or other securities, milestone payments under the Company's distribution and supply agreement with Ortho-Clinical Diagnostics Inc. (“Ortho”) related to MosaiQ and the sale and leaseback of the Company's Biocampus facility in Edinburgh, Scotland. The Company’s Directors are confident in the availability of these funding sources and accordingly have prepared the financial statements on the going concern basis. However, there can be no assurance the Company will be able to obtain adequate financing when necessary and the terms of any financings may not be advantageous to the Company and may result in dilution to its shareholders. On October 24, 2017, the Company entered into subscription agreements for the private placement of (i) 7,874,683 newly issued ordinary shares of the Company at a subscription price of \$4.64 per share, (ii) newly issued warrants of the Company, at a purchase price of \$0.125 per underlying warrant share, exercisable for up to 8,414,683 ordinary shares at an exercise price of \$5.80 per ordinary share, and (iii) newly issued pre-funded warrants of the Company at a purchase price of \$4.755 per underlying pre-funded warrant share, exercisable for up to 550,000 ordinary shares at an



exercise price of \$0.01 per ordinary share. The aggregate gross proceeds of the private placement were \$40.2 million. If the warrants are exercised in full prior to their expiration on July 31, 2018, it would result in additional proceeds of \$48.8 million. However, there can be no assurance that the warrants will be exercised.

## Note 2. Summary of Significant Accounting Policies

### Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates.

### Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. All cash and cash equivalents comprised readily accessible cash balances except for \$5.04 million at each of September 30, 2017 and March 31, 2017 held in a cash reserve account pursuant to the indenture governing the 12% Senior Secured Notes due 2023 (the "Secured

Notes”) and \$313 and \$305 at September 30, 2017 and March 31, 2017, respectively, held in a restricted account as security for the property rental obligations of the Company’s Swiss subsidiary.

#### Short-term Investments

Short-term investments represent investments in a money-market fund which is valued daily and which has no minimum notice period for withdrawals. The fund is invested in a portfolio of holdings and the creditworthiness requirement for individual investment holdings is a minimum of an A rating from a leading credit-rating agency. The Company records the value of its investment in the fund based on the quoted value of the fund at the balance sheet date. Unrealized gains or losses are recorded in accumulated other comprehensive loss and are transferred to the statement of comprehensive loss when they are realized.

#### Trade Accounts Receivable

Trade accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts to reserve for potentially uncollectible trade receivables. Movements in the allowance for doubtful accounts are recorded in General and administrative expenses. The Company reviews its trade receivables to identify specific customers with known disputes or collectability issues. In addition, the Company maintains an allowance for all other receivables not included in the specific reserve by applying specific rates of projected uncollectible receivables to the various aging categories. In determining these percentages, the Company analyzes its historical collection experience, customer credit-worthiness, current economic trends and changes in customer payment terms.

#### Concentration of Credit Risks and Other Uncertainties

The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Derivative instruments, consisting of foreign exchange contracts, and short-term investments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the foreign exchange contracts consist of large financial institutions of high credit standing. The short-term investments are invested in a fund which is invested in a portfolio of holdings and the creditworthiness requirement for individual investment holdings is a minimum of an A rating from a leading credit-rating agency.

The Company’s main financial institutions for banking operations hold all of the Company’s cash and cash equivalents as of September 30, 2017 and at March 31, 2017. The Company’s accounts receivable are derived from net revenue to customers and distributors located in the United States and other countries. The Company performs credit evaluations of its customers’ financial condition. The Company provides reserves for potential credit losses but has not experienced significant losses to date. There was one customer whose accounts receivable balance represented 10% or more of total accounts receivable, net, as of September 30, 2017 and March 31, 2017. This customer represented 48% and 59% of the accounts receivable balances as of September 30, 2017 and March 31, 2017, respectively.

The Company currently sells products through its direct sales force and through third-party distributors. There was one customer that accounted for 10% or more of total product sales for the six month periods ended September 30, 2017 and September 30, 2016. This customer represented 65% of total product sales for the six month period ended September 30, 2017 and 59% for the six month period ended September 30, 2016.

#### Fair Value of Financial Instruments

The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company's valuation techniques used to measure fair value maximized the use of observable inputs and minimized the use of unobservable inputs. The fair value hierarchy is based on the following three levels of inputs:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

See Note 6, "Commitment and Contingencies," for information and related disclosures regarding the Company's fair value measurements.

- 8 -

---

## Inventory

Inventory is stated at the lower of standard cost (which approximates actual cost) or market, with cost determined on the first-in-first-out method. Accordingly, allocation of fixed production overheads to conversion costs is based on normal capacity of production. Abnormal amounts of idle facility expense, freight, handling costs and spoilage are expensed as incurred and not included in overhead. No stock-based compensation cost was included in inventory as of September 30, 2017 and March 31, 2017.

## Property and Equipment

Property, equipment and leasehold improvements are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed on a straight-line basis over the estimated useful lives of the related assets as follows:

Land—not depreciated.

Plant, machinery and equipment—4 to 25 years;

Leasehold improvements—the shorter of the lease term or the estimated useful life of the asset.

Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred.

## Intangible Assets and Goodwill

Intangible assets related to product licenses are recorded at cost, less accumulated amortization. Intangible assets related to technology and other intangible assets acquired in acquisitions are recorded at fair value at the date of acquisition, less accumulated amortization. Intangible assets are amortized over their estimated useful lives, on a straight-line basis as follows:

Customer relationships—5 years

Brands associated with acquired cell lines—40 years

Product licenses—10 years

Other intangibles assets—7 years

The Company reviews its intangible assets for impairment and conducts an impairment review when events or circumstances indicate the carrying value of a long-lived asset may be impaired by estimating the future undiscounted cash flows to be derived from an asset to assess whether or not a potential impairment exists. No impairment losses have been recorded in either of the six month periods ended September 30, 2017 or September 30, 2016.

## Revenue Recognition

The Company recognizes revenue from product sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable and collectability is reasonably assured. Customers have no right of return except in the case of damaged goods. The Company has not experienced any significant returns of its products. Shipping and handling costs are expensed as incurred and included in cost of product sales. In those cases where the Company bills shipping and handling costs to customers, the amounts billed are classified as revenue.

The Company enters into revenue arrangements that may consist of multiple deliverables of its products and services. The terms of these arrangements may include non-refundable upfront payments, milestone payments, other contingent payments and royalties on any product sales derived on collaboration. Up-front fees received in connection with collaborative agreements are deferred upon receipts, are not considered a separate unit of accounting and are recognized as revenues over the relevant performance periods. Revenues related to research and development services included in a collaboration agreement are recognized as research and services are performed over the related performance periods for each contract. A payment that is contingent upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved.

Pursuant to an Umbrella Supply Agreement with Ortho, in June 2013, the Company executed a product attachment relating to the development of a range of rare antisera products. This product attachment was amended in August 2016. During the year ended March 31, 2017, the Company recognized the milestones of \$1,300 related to the completion of the CE marking of the products for use on Ortho's automation platforms and \$800 related to the receipt of FDA approval of certain of the rare antisera products. The Company earned a milestone of \$600 related to the receipt of FDA approval of the rare antisera products in the six month period ended September 30, 2017 and, under the terms of the amended product attachment, the Company is entitled to receive a milestone payment of \$1,500 upon the updating of the FDA approvals to cover use of the products on Ortho's automation platforms.

- 9 -

---

In January 2015, the Company entered into a supply and distribution agreement with Ortho related to the commercialization and distribution of certain MosaiQ products. Under the terms of this agreement, the Company is entitled to receive milestone payments upon CE-mark and FDA approval, as well as upon the first commercial sale of the relevant MosaiQ products by Ortho within the European Union, United States and within any country outside of these two regions. The Company has concluded that as each of these milestones require significant levels of development work to be undertaken and there was no certainty at the start of the projects that the development work would be successful, these milestones are substantive and should be accounted for under the milestone method of revenue recognition.

#### Research and Development

Research and development expenses consist of costs incurred for company-sponsored and collaborative research and development activities. These costs include direct and research-related overhead expenses. The Company expenses research and development costs, including the expenses for research under collaborative agreements, as such costs are incurred. Where government grants or tax credits are available, the income concerned is included as a credit against the related expense.

#### Stock-Based Compensation

Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as an expense on a straight-line basis over the requisite service period, which is generally the vesting period. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company's Consolidated Statements of Comprehensive Loss.

In determining fair value of the stock-based compensation payments, the Company uses the Black-Scholes model and a single option award approach for share options and a barrier option pricing model for multi-year performance based restricted share units ("MRSUs"), both of which require the input of subjective assumptions. These assumptions include: the fair value of the underlying share, estimating the length of time employees will retain their awards before exercising them (expected term), the estimated volatility of the Company's ordinary shares price over the expected term (expected volatility), risk-free interest rate (interest rate), expected dividends and the number of shares subject to awards that will ultimately not complete their vesting requirements (forfeitures).

#### Pension Obligation

The Company maintains a pension plan covering employees in Switzerland pursuant to the requirements of Swiss pension law. Certain aspects of the plan require that it be accounted for as a defined benefit plan pursuant to Accounting Standards Codification Topic, 715 Compensation – Retirement Benefits ("ASC 715"). The Company recognizes an asset for the plan's overfunded status or a liability for the plan's underfunded status in its Consolidated Balance Sheets. Additionally, the Company measures the plan's assets and obligations that determine its funded status as of the end of the year and recognizes the change in the funded status within "Accumulated other comprehensive loss".

The Company uses an actuarial valuation to determine its pension benefit costs and credits. The amounts calculated depend on a variety of key assumptions, including discount rates and expected return on plan assets. Details of the assumptions used to determine the net funded status are set out in the notes to the Company's March 31, 2017 financial statements. The Company's pension plan assets are assigned to their respective levels in the fair value hierarchy in accordance with the valuation principles described in the "Fair Value of Financial Instruments" section above.

## Note 3. Intangible Assets

	September 30, 2017			Weighted
	Gross			Average
	Carrying	Accumulated	Net Carrying	Remaining
	Amount	Amortization	Amount	Useful Life
Customer relationships	\$2,637	\$ (2,637 )	\$ —	—
Brands associated with acquired cell lines	544	(137 )	407	29.9 years
Product licenses	837	(397 )	440	5.3 years
Other intangibles	171	(171 )	—	—
Total	\$4,189	\$ (3,342 )	\$ 847	17.1 years

- 10 -

	March 31, 2017			Weighted
	Gross Carrying Amount			Average
	Accumulated	Net Carrying	Amount	Remaining
	Amount	Amortization	Amount	Useful Life
Customer relationships	\$2,458	\$ (2,458 )	\$ —	—
Brands associated with acquired cell lines	507	(121 )	386	30.4 years
Product licenses	716	(333 )	383	5.4 years
Other intangibles	160	(160 )	—	—
Total	\$3,841	\$ (3,072 )	\$ 769	17.9 years

#### Note 4. Debt

Long-term debt comprises:

	September 30, 2017	March 31, 2017
Total debt	\$ 84,000	\$ 84,000
Less current portion	—	—
Long-term debt	\$ 84,000	\$ 84,000
Deferred debt costs, net of amortization	(414 )	(3,296 )
	\$ 83,586	\$ 80,704

The Company's debt at September 30, 2017 comprises the Secured Notes issued on October 14, 2016. On that date, the Company completed the private placement of up to \$120 million aggregate principal amount of the Secured Notes and entered into an indenture governing the Secured Notes with the guarantors party thereto and U.S. Bank National Association, a national banking association, as trustee and collateral agent. The obligations of the Company under the indenture and the Secured Notes are unconditionally guaranteed on a secured basis by the guarantors, which include all the Company's subsidiaries, and the indenture governing the Secured Notes contains customary events of default. The Company and its subsidiaries must also comply with certain customary affirmative and negative covenants, including a requirement to maintain six-months of interest in a cash reserve account maintained with the collateral agent.

The Company issued \$84 million aggregate principal amount of the Secured Notes on October 14, 2016 and, so long as no event of default has occurred, the Company will issue an additional \$36 million aggregate principal amount of the Secured Notes upon public announcement of field trial results for the MosaiQ IH Microarray that demonstrates greater than 99% concordance for the detection of blood group antigens and greater than 95% concordance for the detection of blood group antibodies when compared to predicate technologies for a pre-defined set of blood group



antigens and antibodies. The Company paid \$5 million of the net proceeds into the cash reserve account maintained with the collateral agent under the terms of the indenture.

Interest on the Secured Notes accrues at a rate of 12% per annum and is payable semi-annually on April 15 and October 15 of each year commencing on April 15, 2017. Commencing on April 15, 2019, the Company will also pay an installment of principal of the Secured Notes on each April 15 and October 15 until October 15, 2023 pursuant to a fixed amortization schedule.

In connection with the offering on October 14, 2016, the Company entered into royalty rights agreements, pursuant to which the Company sold to the note purchasers in the offering, the right to receive an aggregate payment equal to 2.0% of the aggregate net sales of MosaiQ instruments and consumables made in the donor testing market in the United States and the European Union. The royalty will be payable beginning on the date that the Company or its affiliates enters into a contract for the sale of MosaiQ instruments or consumables in the donor testing market in the European Union or the United States and will end on the last day of the calendar quarter in which the eighth anniversary of the first contract date occurs. The royalty rights agreements are treated as sales of future revenues that meet the requirements of Accounting Standards Codification Topic 470 "Debt" to be treated as debt. The estimated future cash outflows under the royalty rights agreements have been combined with the Secured Notes issuance costs and interest payable to calculate the effective interest rate of the Secured Notes and will be expensed through interest expenses using the effective interest rate method over the term of the Secured Notes and royalty rights agreements. Estimating the future cash outflows under the royalty rights agreements requires the Company to make certain estimates and assumptions about future sales of MosaiQ products. These estimates of the magnitude and timing of MosaiQ sales are subject to significant variability due to the current status of development of MosaiQ products, and thus are subject to significant uncertainty. Therefore, the estimates are likely to change as the Company gains experience of marketing MosaiQ, which may result in future adjustments to the accretion of the interest expense and amortized cost based carrying value of the Secured Notes.

At September 30, 2017, the outstanding debt was repayable as follows:

Within 1 year	\$—
Between 1 and 2 years	6,720
Between 2 and 3 years	13,440
Between 3 and 4 years	15,960
Between 4 and 5 years	17,640
After 5 years	30,240
Total debt	\$84,000

#### Note 5. Consolidated Balance Sheet Detail

##### Inventory

The following table summarizes inventory by category for the dates presented:

	September 30, 2017	March 31, 2017
Raw materials	\$ 10,253	\$8,993
Work in progress	3,183	3,260
Finished goods	1,787	1,383
Total inventories	\$ 15,223	\$13,636

Inventory at September 30, 2017, included \$8,582 of raw materials, \$1,226 of work in progress and \$241 of finished goods related to the MosaiQ project. Inventory at March 31, 2017, included \$7,659 of raw materials and \$1,415 of work in progress related to the MosaiQ project.

##### Property and equipment

The following table summarizes property and equipment by categories for the dates presented:

	September 30, 2017	March 31, 2017
Land	\$ 1,254	\$1,286
Plant and equipment	49,368	44,797

Edgar Filing: Quotient Ltd - Form 10-Q

Leasehold improvements	44,894	32,343
Total property and equipment	95,516	78,426
Less: accumulated depreciation	(20,625 )	(14,896)
Total property and equipment, net	\$ 74,891	\$ 63,530

Depreciation expenses were \$2,594 and \$2,251 in the quarters ended September 30, 2017 and September 30, 2016, respectively, and \$5,036 and \$4,430 in the six month periods ended September 30, 2017 and September 30, 2016, respectively.

Accrued compensation and benefits

Accrued compensation and benefits consist of the following:

	September 30,	March 31,
	2017	2017
Salary and related benefits	\$ 1,140	\$403
Accrued vacation	263	413
Accrued payroll taxes	478	325
Accrued incentive payments	1,250	2,500
Total accrued compensation and benefits	\$ 3,131	\$3,641

## Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following:

	September 30, 2017	March 31, 2017
Accrued legal and professional fees	\$ 299	\$449
Accrued interest	4,625	4,640
Goods received not invoiced	1,292	932
Accrued capital expenditure	5,596	1,387
Accrued development expenditure	4,308	4,187
Other accrued expenses	1,744	1,914
<b>Total accrued expenses and other current liabilities</b>	<b>\$ 17,864</b>	<b>\$ 13,509</b>

## Note 6. Commitments and Contingencies

## Government grant

In 2008, the Company was awarded research and development grant funding from Scottish Enterprise amounting to £1,791, for the development of MosaiQ. The total grant claimed to September 30, 2017 is £1,790. The Company updates Scottish Enterprise periodically with the status of the project and, while the terms of the grant award provide for full repayment of the grant in certain circumstances, the Company does not consider that any repayment is likely.

## Hedging arrangements

The Company's subsidiary in the United Kingdom ("UK") has entered into six contracts to sell \$500 in each calendar month from October 2017 through March 2018 at £1:\$1.2655 and three contracts to sell \$500 and purchase pounds sterling at £1:\$1.2990 in each calendar month from April 2018 through June 2018 as hedges of its U.S. dollar denominated revenues.

## Fair value measurements

The following table summarizes the Company's assets and liabilities that are measured at fair value on a recurring basis, by level, within the fair value hierarchy:

	September 30, 2017			Total
	Level 1	Level 2	Level 3	
<b>Assets:</b>				
Pension plan assets (1)	\$—	\$9,643	\$ —	\$9,643

Edgar Filing: Quotient Ltd - Form 10-Q

Short-term investments (2)	10,686	—	—	10,686
Foreign currency forward contracts (3)	—	221	—	221
Total assets measured at fair value	\$10,686	\$9,864	\$ —	\$20,550

	September 30, 2017			
	Level 1	Level 2	Level 3	Total
<b>Liabilities:</b>				
Foreign currency forward contracts (3)	\$—	\$ —	\$ —	\$ —
Total liabilities measured at fair value	\$—	\$ —	\$ —	\$ —

	March 31, 2017			
	Level 1	Level 2	Level 3	Total
<b>Assets:</b>				
Pension plan assets (1)	\$—	\$7,981	\$ —	\$7,981
Short-term investments (2)	16,057	—	—	16,057
Total assets measured at fair value	\$16,057	\$7,981	\$ —	\$24,038

	March 31, 2017			Total
	Level	Level	Level	
	1	2	3	
<b>Liabilities:</b>				
Foreign currency forward contracts (3)	\$—	\$252	\$—	\$252
Total liabilities measured at fair value	\$—	\$252	\$—	\$252

- (1) The fair value of pension plan assets has been determined as the surrender value of the portfolio of active insured employees held within the Swiss Life collective investment fund. See Note 9, “Defined Benefit Pension Plans”.
- (2) The fair value of short-term investments has been determined based on the quoted value of the units held in the money market fund at the balance sheet date. See Note 2, “Summary of Significant Accounting Policies – Short-term Investments”.
- (3) The fair value of foreign currency forward contracts has been determined by calculating the present value of future cash flows, estimated using market-based observable inputs including forward and spot exchange rates and interest rate curves obtained from third party market price quotations.

#### Note 7. Ordinary and Preference Shares

##### Ordinary shares

The Company’s issued and outstanding ordinary shares were as follows:

	Shares Issued and Outstanding September 30,		Par value
	2017	March 31, 2017	
Ordinary shares	37,694,531	29,567,698	\$ —
Total	37,694,531	29,567,698	\$ —

##### Preference shares

The Company’s issued and outstanding preference shares consist of the following:

Shares Issued and Outstanding	Liquidation amount per share
----------------------------------	------------------------------------

Edgar Filing: Quotient Ltd - Form 10-Q

	September 30,	March 31,	September 30,	March 31,
	2017	2017	2017	2017
<b>7% Cumulative Redeemable</b>				
Preference shares	666,665	666,665	\$26.71	\$25.92
Total	666,665	666,665		

Note 8. Share-Based Compensation

The Company records share-based compensation expense in respect of options, multi-year performance based restricted share units (“MRSUs”) and restricted share units (“RSUs”) issued under its share incentive plans. Share-based compensation expense amounted to \$1,187 and \$1,083 in the quarters ended September 30, 2017 and September 30, 2016, respectively, and \$2,472 and \$1,981 in the six month periods ended September 30, 2017 and September 30, 2016, respectively.

- 14 -

---

## Share option activity

The following table summarizes share option activity:

	Number of Share Options Outstanding	Weighted Average Exercise Price	Weighted Average Remaining Contractual Life (Months)
Outstanding — March 31, 2017	1,948,917	\$ 8.04	90
Granted	309,525	7.55	120
Exercised	(33,520 )	3.21	—
Forfeited	(17,200 )	11.14	—
Outstanding — September 30, 2017	2,207,722	\$ 8.02	89
Exercisable — September 30, 2017	1,420,382	\$ 7.40	78

The closing price of the Company's ordinary shares on The NASDAQ Global Market at September 30, 2017 was \$4.93.

The following table summarizes the options granted in the current financial year with their exercise prices, the fair value of ordinary shares as of the applicable grant date, and the intrinsic value:

Grant Date	Number of Options Granted	Exercise Price	Ordinary Shares Fair Value Per Share at Grant Date	Per Share Intrinsic Value of Options
May 24, 2017	305,525	\$ 7.58	\$ 7.58	\$ 4.62
August 9, 2017	4,000	\$ 5.41	\$ 5.41	\$ 3.34

Determining the fair value of share incentive awards



The fair value of each share incentive grant was determined by the Company using the Black-Scholes options pricing model.

Assumptions used in the option pricing models are discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.

**Expected volatility.** The expected volatility was based on the historical share volatilities of a number of the Company's publicly listed peers over a period equal to the expected terms of the options as the Company did not have a sufficient trading history to use the volatility of its own ordinary shares.

**Fair value of ordinary shares.** The fair value of the ordinary shares is based upon the closing price of the Company's shares on The NASDAQ Global Market on the last trading day prior to the date of grant.

**Risk-Free Interest Rate.** The risk-free interest rate is based on the US Treasury 10-year bond yield in effect at the time of grant.

**Expected term.** The expected term is determined after giving consideration to the contractual terms of the share-based awards, graded vesting schedules ranging from one to three years and expectations of future employee behavior as influenced by changes to the terms of its share-based awards.

**Expected dividend.** According to the terms of the awards, the exercise price of the options is adjusted to take into account any dividends paid. As a result dividends are not required as an input to the model, as these reductions in the share price are offset by a corresponding reduction in exercise price.

A summary of the assumptions applicable to the share options issued in the current financial year is as follows:

	May 24, 2017	August 9, 2017
Risk-free interest rate	2.28 %	2.25 %
Expected lives (years)	6	6
Volatility	66.10 %	67.17 %
Dividend yield	—	—
Grant date fair value (per share)	\$ 7.58	\$ 5.41
Number granted	305,525	4,000

A summary of the RSUs and MRSUs in issue at September 30, 2017 is as follows:

	Number of RSUs or MRSUs	Weighted Average Remaining Vesting Period (Months)	Period in which the target must be achieved
RSUs subject to time based vesting	294,063	15	N/A
RSUs subject to MosaiQ milestone vesting	290,000	N/A	N/A
MRSUs with vesting based on \$60 share price	114,500	N/A	Apr - Dec 2018
MRSUs with vesting based on \$40 share price	127,000	N/A	Apr - Dec 2018
MRSUs with vesting based on \$22 share price	166,000	N/A	Apr - Dec 2019

At September 30, 2017, 294,063 RSUs were subject to time based vesting and the weighted average remaining vesting period was 15 months. In addition, 290,000 RSUs were subject to vesting based on the achievement of various milestones relating to the development, approval and marketing of MosaiQ. 166,000 MRSUs were awarded on May 24, 2017, which will vest if the volume weighted average price of the Company's ordinary shares exceeds \$22 for a continuous twenty day period between April 1, 2019 and December 31, 2019. The Company determined the grant date fair value of these MRSUs using a barrier option pricing model with the same grant date fair value per share, risk free interest rate, volatility and dividend yield assumptions as the options awarded on the same date. This resulted in a grant date fair value of \$3.20 per MRSU on May 24, 2017. The remainder of the MRSUs in issue at September 30, 2017 comprised 114,500 MRSUs, which will vest between April 1, 2018 and December 31, 2018 if the Company's ordinary share price exceeds \$60 for 20 consecutive days in this period, and 127,000 MRSUs, which will vest between April 1, 2018 and December 31, 2018 if the Company's ordinary share price exceeds \$40 for 20 consecutive days in this period.

## Note 9. Defined Benefit Pension Plans

The Company's Swiss subsidiary has a fully insured pension plan managed by Swiss Life. The costs of this plan were:

	Quarter ended September 30, 2017		Six months ended September 30, 2016	
Employer service cost	\$398	\$341	\$791	\$685
Interest cost	27	10	54	20
Expected return on plan assets	(29)	(16)	(57)	(31)
Amortization of prior service credit	(3)	—	(7)	—
Amortization of net loss	47	43	93	87
Net pension cost for the year	\$440	\$378	\$874	\$761

The employer contributions for the six month periods ended September 30, 2017 and 2016 were \$545 and \$417, respectively. The estimated employer contributions for the fiscal year ending March 31, 2018 are \$1,031.

## Note 10. Net Loss Per Share

In accordance with Accounting Standards Codification Topic 260 “Earnings Per Share”, basic earnings available to ordinary shareholders per share is computed based on the weighted average number of ordinary shares outstanding during each period. Diluted earnings available to ordinary shareholders per share is computed based on the weighted average number of ordinary shares outstanding during each period, plus potential ordinary shares considered outstanding during the period, as long as the inclusion of such shares is not anti-dilutive. Potential ordinary shares consist of the incremental ordinary shares issuable upon the exercise of share options (using the treasury shares method), the warrants to acquire ordinary shares and the ordinary shares issuable upon vesting of the MRSUs and RSUs.

The following table sets forth the computation of basic and diluted earnings per ordinary share.

	Quarter ended September 30, 2017		Six months ended September 30, 2016	
<b>Numerator:</b>				
Net loss	\$ (21,692 )	\$ (17,358 )	\$ (41,929 )	\$ (33,593 )
Net loss available to ordinary shareholders - basic and diluted	\$ (21,692 )	\$ (17,358 )	\$ (41,929 )	\$ (33,593 )
<b>Denominator:</b>				
<b>Weighted-average shares</b>				
outstanding - basic and diluted	37,657,409	28,123,334	37,223,957	26,774,378
Loss per share - basic and diluted	\$ (0.58 )	\$ (0.62 )	\$ (1.13 )	\$ (1.25 )

The following table sets out the numbers of ordinary shares excluded from the above computation of earnings per share at September 30, 2017 and September 30, 2016 as their inclusion would have been anti-dilutive.

	September 30, 2017	September 30, 2016
<b>Ordinary shares issuable on exercise of options to purchase</b>		
ordinary shares	2,207,722	1,806,668
<b>Restricted share units awarded, including the multi-year</b>		
performance related restricted share units	991,563	627,287
<b>Ordinary shares issuable on exercise of warrants at \$16.14 per</b>		
share	111,525	111,525
Ordinary shares issuable on exercise of warrants at \$9.37 per	64,000	64,000

share

3,374,810 2,609,480

Note 11. Subsequent Events

On October 24, 2017, the Company entered into subscription agreements for the private placement of (i) 7,874,683 newly issued ordinary shares of the Company at a subscription price of \$4.64 per share, (ii) newly issued warrants of the Company, at a purchase price of \$0.125 per underlying warrant share, exercisable for up to 8,414,683 ordinary shares at an exercise price of \$5.80 per ordinary share, and (iii) newly issued pre-funded warrants of the Company at a purchase price of \$4.755 per underlying pre-funded warrant share, exercisable for up to 550,000 ordinary shares at an exercise price of \$0.01 per ordinary share. The aggregate gross proceeds were \$40.2 million.

## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with the corresponding section of our Annual Report on Form 10-K for the year ended March 31, 2017 filed with the Securities and Exchange Commission on May 25, 2017.

The information set forth and discussed below for the quarters and six month periods ended September 30, 2017 and September 30, 2016 is derived from the Condensed Consolidated Financial Statements included under Item 1 above. The financial information set forth and discussed below is unaudited but includes all adjustments (consisting of normal recurring adjustments) that our management considers necessary for a fair presentation of the financial position and the operating results and cash flows for those periods. Our results of operations for a particular quarter may not be indicative of the results that may be expected for other quarters or the entire year.

### Overview

We were incorporated in Jersey, Channel Islands on January 28, 2012. On February 16, 2012, we acquired the entire issued share capital of Alba Bioscience Limited (or Alba), Quotient Biodiagnostics, Inc. (or QBDI) and QBD (QSIP) Limited (or QSIP) from Quotient Biodiagnostics Group Limited (or QBDG), our predecessor.

The acquisition of Alba, QBDI and QSIP by us is treated for accounting purposes as a combination of entities under common control as these entities were all controlled by QBDG prior to their acquisition by us. We recognized the assets and liabilities of Alba, QBDI and QSIP at their carrying amounts in the financial statements of those companies. We are a continuation of QBDG and its subsidiaries and, accordingly, our consolidated financial statements include the assets, liabilities and results of operations of the subsidiaries transferred since their inception.

### Our Business

We are a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. Our initial focus is on blood grouping and donor disease screening, which is commonly referred to as transfusion diagnostics. Blood grouping involves specific procedures performed at donor or patient testing laboratories to characterize blood, which includes antigen typing and antibody identification. Disease screening involves the screening of donor blood for unwanted pathogens using two different methods, a serological approach (testing for specific antigens or antibodies) and a molecular approach (testing for DNA or RNA).

We have over 30 years of experience developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. We are developing MosaiQ, our proprietary technology platform, to better address the comprehensive needs of this large and established market. MosaiQ will initially comprise two separate microarrays, one for immunohematology and one for serological disease screening, and a high-throughput instrument. We are also developing a third microarray for molecular disease screening. We believe MosaiQ has the potential to transform transfusion diagnostics, significantly reducing the cost of blood grouping in the donor and patient testing environments, while improving patient outcomes.

We operate as one business segment with 409 employees in the United States, the United Kingdom and Switzerland as of September 30, 2017. Our principal markets are the United States, Europe and Japan. Based on the location of the customer, revenues outside the United States accounted for 51% and 48% of total revenue during the six month periods ended September 30, 2017 and September 30, 2016, respectively.

We have incurred net losses and negative cash flows from operations in each year since we commenced operations in 2007. As of September 30, 2017, we had an accumulated deficit of \$235.2 million. We expect our operating losses to

continue for at least the remainder of the current fiscal year as we continue our investment in the development and commercialization of MosaiQ. For the six month period ended September 30, 2017, our total revenue was \$12.7 million and our net loss was \$41.9 million.

From our incorporation in 2012 to March 31, 2017, we have raised \$70.6 million of gross proceeds through the private placement of our ordinary and preference shares and warrants, \$132.8 million of gross proceeds from public offerings of our shares and warrants and \$84.0 million of gross proceeds from the issuance of 12% Senior Secured Notes (“the Secured Notes”). On April 10, 2017, we completed a public offering of 8,050,000 newly issued ordinary shares at a price of \$6.00 per share which raised \$48.3 million of gross proceeds before underwriting discounts and other offering expenses. As of September 30, 2017, we had cash and cash equivalents and short-term investments of \$24.9 million, including \$5.4 million of cash held in restricted accounts as part of the arrangements relating to our Secured Notes and the lease of our property in Eysins, Switzerland.

On October 24, 2017, we entered into subscription agreements for the private placement of (i) 7,874,683 newly issued ordinary shares at a subscription price of \$4.64 per share, (ii) newly issued warrants, at a purchase price of \$0.125 per underlying warrant share,

- 18 -

---

exercisable for up to 8,414,683 ordinary shares at an exercise price of \$5.80 per ordinary share, and (iii) newly issued pre-funded warrants, at a purchase price of \$4.755 per underlying pre-funded warrant share, exercisable for up to 550,000 ordinary shares at an exercise price of \$0.01 per ordinary share. The aggregate gross proceeds were \$40.2 million. If the warrants are exercised in full prior to their expiration on July 31, 2018, it would result in additional proceeds of \$48.8 million. However, there can be no assurance that the warrants will be exercised.

## Revenue

We generate revenue from the sale of conventional reagent products directly to hospitals, donor collection agencies and independent testing laboratories in the United States, the United Kingdom and to distributors in Europe and the rest of the world, and indirectly through sales to our original equipment manufacturer (or OEM) customers. We recognize revenues in the form of product sales when the goods are shipped. Products sold by standing purchase orders as a percentage of product sales revenue were 74% and 75% for the six month periods ended September 30, 2017 and September 30, 2016, respectively. We also provide product development services to our OEM customers. We recognize revenue from these contractual relationships in the form of product development fees, which are included in other revenues. For a description of our revenue recognition policies, see “—Critical Accounting Policies and Significant Judgments and Estimates—Revenue Recognition and Accounts Receivable.”

Our revenue is denominated in multiple currencies. Sales in the United States and to certain of our OEM customers are denominated in U.S. Dollars. Sales in Europe and the rest of the world are denominated primarily in U.S. Dollars, Pounds Sterling or Euros. Our expenses are generally denominated in the currencies in which our operations are located, which are primarily in the United Kingdom, Switzerland and the United States. We operate globally and therefore changes in foreign currency exchange rates may become material to us in the future due to factors beyond our control. See “—Quantitative and Qualitative Disclosure About Market Risk—Foreign Currency Exchange Risk.”

## Cost of revenue and operating expenses

Cost of revenue consists of direct labor expenses, including employee benefits, overhead expenses, material costs and freight costs, along with the depreciation of manufacturing equipment and leasehold improvements. Cost of revenue is also affected by manufacturing efficiencies and allowances for scrapped or expired material. Our gross profit represents total revenue less the cost of revenue and gross margin represents gross profit expressed as a percentage of total revenue. Our gross margin was 56% and 51% for the six month periods ended September 30, 2017 and September 30, 2016, respectively. Excluding other revenues, which consist of product development fees, our gross margin on product sales was 54% and 45% for the six month periods ended September 30, 2017 and September 30, 2016, respectively. We expect our overall cost of revenue to increase in absolute U.S. Dollars as we continue to increase our product sales volumes. However, we also believe that we can achieve efficiencies in our manufacturing operations, primarily through increasing production volumes.

Our sales and marketing expenses include costs associated with our sales organization for conventional reagent products, including our direct sales force, as well as our marketing and customer service personnel and our MosaiQ commercial team. These expenses consist principally of salaries, commissions, bonuses and employee benefits, as well as travel and other costs related to our sales and product marketing activities. We expense all sales and marketing costs as incurred. We expect sales and marketing expense to increase in absolute U.S. Dollars, primarily as a result of commissions on increased product sales in the United States and as we grow the MosaiQ commercial team.

Our research and development expenses include costs associated with performing research, development, field trials and our regulatory activities, as well as production costs incurred in advance of the commercial launch of MosaiQ. Research and development expenses include research personnel-related expenses, fees for contractual and consulting services, travel costs, laboratory supplies and depreciation of laboratory equipment.



We expense all research and development costs as incurred, net of government grants received and tax credits. Our UK subsidiary is able to claim certain tax credits on its research and development expenditures. Our research and development efforts are focused on developing new products and technologies for the global transfusion diagnostics market. We segregate research and development expenses for the MosaiQ project from expenses for other research and development projects. We do not maintain detailed records of these other costs by activity. We are nearing completion of the initial development of MosaiQ and as we move to commercialization, we expect overall research and development expense to decrease.

Our general and administrative expenses include costs for our executive, accounting and finance, legal, corporate development, information technology and human resources functions. We expense all general and administrative expenses as incurred. These expenses consist principally of salaries, bonuses and employee benefits for the personnel performing these functions, including travel costs. These expenses also include share-based compensation, professional service fees (such as audit, tax and legal fees), costs related to our Board of Directors, and general corporate overhead costs, which include depreciation and amortization. We expect our general

- 19 -

---

and administrative expenses to increase as our business develops and also due to the costs of operating as a public company, such as additional legal, accounting and corporate governance expenses, including expenses related to compliance with the Sarbanes-Oxley Act, directors' and officers' insurance premiums and investor relations expenses.

Net interest expense consists primarily of interest charges on our note and loan balances and the amortization of debt issuance costs, as well as accrued dividends on the 7% cumulative redeemable preference shares issued in January 2015. We amortize debt issuance costs over the life of the note or loan and report them as interest expense in our statements of operations. Net interest also includes the expected costs of the royalty rights agreements we entered into in October 2016 with the purchasers of our Secured Notes. See Note 4 "Debt" and Note 7 "Ordinary and Preference Shares – Preference shares" to our condensed consolidated financial statements included in this Quarterly Report for additional information.

Other income (expense), net consists primarily of exchange fluctuations. These include realized exchange fluctuations resulting from the settlement of transactions in currencies other than the functional currencies of our businesses. Monetary assets and liabilities that are denominated in foreign currencies are measured at the period-end closing rate with resulting unrealized exchange fluctuations. The functional currencies of our businesses are Pounds Sterling, Swiss Francs and U.S. Dollars depending on the entity.

## Results of Operations

### Comparison of the Quarters ended September 30, 2017 and 2016

The following table sets forth, for the periods indicated, the amounts of certain components of our statements of operations and the percentage of total revenue represented by these items, showing period-to-period changes.

	Quarter ended September 30,		2016	Amount	% of revenue	Change	Amount	%
	2017	Amount						
(in thousands, except percentages)								
<b>Revenue:</b>								
Product sales	\$5,910	100	%	\$4,844	79	%	\$1,066	22
Other revenues	—	0	%	1,300	21	%	(1,300)	-100
Total revenue	5,910	100	%	6,144	100	%	(234)	-4
Cost of revenue	2,786	47	%	2,761	45	%	25	1
Gross profit	3,124	53	%	3,383	55	%	(259)	-8
<b>Operating expenses:</b>								
Sales and marketing	1,869	32	%	1,273	21	%	596	47
Research and development	13,341	226	%	14,495	236	%	(1,154)	-8
General and administrative	5,974	101	%	5,126	83	%	848	17
Total operating expenses	21,184	358	%	20,894	340	%	290	1
Operating loss	(18,060)	-306	%	(17,511)	-285	%	(549)	3
<b>Other income (expense):</b>								
Interest expense, net	(4,197)	-71	%	(1,213)	-20	%	(2,984)	246
Other, net	565	10	%	1,366	22	%	(801)	-59
Total other income (expense), net	(3,632)	-61	%	153	2	%	(3,785)	—
Loss before income taxes	(21,692)	-367	%	(17,358)	-283	%	(4,334)	25
Provision for income taxes	—	—		—	—		—	—

Net loss	\$ (21,692)	-367	%	\$ (17,358)	-283	%	\$ (4,334)	25	%
----------	-------------	------	---	-------------	------	---	------------	----	---

## Revenue

Total revenue for the quarter ended September 30, 2017 decreased by 4% to \$5.9 million, compared with \$6.1 million for the quarter ended September 30, 2016. In the quarter ended September 30, 2016 other revenues included \$1.3 million of product development fees which did not recur in the quarter ended September 30, 2017. Product sales revenue increased 22% to \$5.9 million for the quarter ended September 30, 2017, compared with \$4.8 million for the quarter ended September 30, 2016. The increase in product sales was primarily attributable to growth in product sales to OEM customers and incremental direct sales of conventional reagent products to customers in the United States. Products sold by standing purchase order were 68% of product sales for the quarter ended September 30, 2017, compared with 73% for the quarter ended September 30, 2016.

- 20 -

---

The below table sets forth revenue by product group:

	Quarter ended September 30,				Change	
	2017		2016		Amount	%
	Amount	% of revenue	Amount	% of revenue	Amount	%
(in thousands, except percentages)						
<b>Revenue:</b>						
Product sales - OEM customers	\$4,235	72 %	\$3,447	56 %	\$788	23 %
Product sales - direct customers and distributors	\$1,675	28 %	1,397	23 %	278	20 %
Other revenues	—	0 %	1,300	21 %	(1,300)	—
<b>Total revenue</b>	<b>\$5,910</b>	<b>100 %</b>	<b>\$6,144</b>	<b>100 %</b>	<b>\$(234)</b>	<b>-4 %</b>

OEM Sales. Product sales to OEM customers increased 23% to \$4.2 million for the quarter ended September 30, 2017, compared with \$3.4 million for the quarter ended September 30, 2016. The increase was due to increased sales to existing customers and the impact of recently launched new products.

Direct Sales to Customers and Distributors. Direct product sales of \$1.7 million for the quarter ended September 30, 2017 increased by \$0.3 million compared with \$1.4 million for the quarter ended September 30, 2016. This mainly consisted of direct sales in the United States which increased to \$1.4 million in the quarter ended September 30, 2017 compared with \$1.3 million in the quarter ended September 30, 2016 as a result of recent product launches and the expansion of our customer base.

Other Revenues. Other revenues of \$1.3 million in the quarter ended September 30, 2016 consisted of product development fees as the result of the achievement of a product development milestone under the terms of our umbrella supply agreement with Ortho-Clinical Diagnostics Inc., or Ortho. See Note 2 “Summary of Significant Accounting Policies — Revenue Recognition” to our condensed consolidated financial statements included in this Quarterly Report for additional information. There were no such revenues in the quarter ended September 30, 2017.

#### Cost of revenue and gross margin

Cost of revenue increased by 1% to \$2.8 million for the quarter ended September 30, 2017, compared with \$2.8 million for the quarter ended September 30, 2016. Cost of revenue reflected incremental costs associated with greater sales volumes, which were offset by improved product mix and efficiencies in our manufacturing operations.

Gross profit on total revenue for the quarter ended September 30, 2017 was \$3.1 million, a decrease of 8% compared with \$3.4 million in the quarter ended September 30, 2016. This decrease was attributable to \$1.3 million of other revenues in the quarter ended September 30, 2016, which had no corresponding cost and did not recur in the quarter ended September 30, 2017, and the increase in gross margin on product sales described below.

Gross margin, which represents gross profit expressed as a percentage of total revenue, was 53% for the quarter ended September 30, 2017, compared with 55% for the quarter ended September 30, 2016. Gross margin on product sales, which excludes other revenues, was 53% for the quarter ended September 30, 2017 compared with 43% for the quarter ended September 30, 2016, due to the positive impact of our revenue hedging arrangements in the quarter ended September 30, 2017 compared with the quarter ended September 30, 2016, improved product and customer mix

and efficiencies at our manufacturing facility in Edinburgh, Scotland.

Sales and marketing expenses

Sales and marketing expense was \$1.9 million for the quarter ended September 30, 2017, compared with \$1.3 million for the quarter ended September 30, 2016. As a percentage of total revenue, sales and marketing expenses were 32% for the quarter ended September 30, 2017, compared with 21% for the quarter ended September 30, 2016. The growth in sales and marketing expense in the quarter ended September 30, 2017 was attributable to increased costs of the MosaiQ commercial team, which was established in April 2016.

- 21 -

---

## Research and development expenses

	Quarter ended September 30, 2017		2016		Change	
	Amount	% of revenue	Amount	% of revenue	Amount	%
(in thousands, except percentages)						
<b>Research and development expenses:</b>						
MosaiQ research and development	\$ 13,073	221 %	\$ 14,051	229 %	\$(978 )	-7 %
Other research and development	336	6 %	507	8 %	(171 )	-34 %
Tax credits	(68 )	-1 %	(63 )	-1 %	(5 )	8 %
<b>Total research and development expenses</b>	<b>\$ 13,341</b>	<b>226 %</b>	<b>\$ 14,495</b>	<b>236 %</b>	<b>\$(1,154)</b>	<b>-8 %</b>

Research and development expenses decreased by 8% to \$13.3 million for the quarter ended September 30, 2017, compared with \$14.5 million for the quarter ended September 30, 2016. As a percentage of total revenue, research and development expenses decreased to 226% for the quarter ended September 30, 2017, compared with 236% for the quarter ended September 30, 2016. The decrease in costs mainly reflected reduced expenditure with our development partners as the initial development of MosaiQ nears completion.

## General and administrative expenses

General and administrative expenses increased by 17% to \$6.0 million for the quarter ended September 30, 2017, compared with \$5.1 million for the quarter ended September 30, 2016, reflecting greater personnel-related costs as we move towards commercialization of MosaiQ and the relocation of our manufacturing facility in Scotland. We recognized \$1.2 million of stock compensation expense in the quarter ended September 30, 2017 compared with \$1.1 million in the quarter ended September 30, 2016. As a percentage of total revenue, general and administrative expenses increased to 101% for the quarter ended September 30, 2017, compared with 83% for the quarter ended September 30, 2016.

## Other income (expense)

Net interest expense was \$4.2 million for the quarter ended September 30, 2017, compared with \$1.2 million for the quarter ended September 30, 2016. Interest expense in the quarter ended September 30, 2017 included \$2.5 million of interest charges on our Secured Notes. Interest expense in the quarter ended September 30, 2016 included interest charges of \$0.7 million on our borrowings of \$30 million from MidCap Financial Trust (or MidCap), which bore interest at LIBOR plus 6.7% (with a LIBOR floor of 2.00%). Interest expense in the quarters ended September 30, 2017 and September 30, 2016 included amortization of deferred debt issue costs of \$1.4 million and \$0.3 million, respectively. In the quarter ended September 30, 2017, this included amortization of the expected costs of the royalty rights agreements entered into in October 2016 in connection with the issuance of the Secured Notes. Net interest expense also included \$0.3 million of dividends accrued on the 7% cumulative redeemable preference shares in each of the quarters ended September 30, 2017 and September 30, 2016.

Other income for the quarters ended September 30, 2017 and September 30, 2016 included \$0.6 million and \$1.4 million, respectively, of foreign exchange gains arising on monetary assets and liabilities denominated in foreign currencies.



## Comparison of the six month periods ended September 30, 2017 and 2016

The following table sets forth, for the periods indicated, the amounts of certain components of our statements of operations and the percentage of total revenue represented by these items, showing period-to-period changes.

	Six months ended September 30, 2017		2016		Change	
	Amount	% of revenue	Amount	% of revenue	Amount	%
(in thousands, except percentages)						
<b>Revenue:</b>						
Product sales	\$12,136	95	% \$10,561	89	% \$1,575	15
Other revenues	600	5	% 1,300	11	% (700 )	-54
Total revenue	12,736	100	% 11,861	100	% 875	7
Cost of revenue	5,618	44	% 5,852	49	% (234 )	-4
Gross profit	7,118	56	% 6,009	51	% 1,109	18
<b>Operating expenses:</b>						
Sales and marketing	3,551	28	% 2,530	21	% 1,021	40
Research and development	26,014	204	% 26,296	222	% (282 )	-1
General and administrative	12,519	98	% 11,072	93	% 1,447	13
Total operating expenses	42,084	330	% 39,898	336	% 2,186	5
Operating (loss)	(34,966)	-275	% (33,889)	-286	% (1,077)	3
<b>Other income (expense):</b>						
Interest expense, net	(8,407 )	-66	% (2,384 )	-20	% (6,023)	253
Other, net	1,444	11	% 2,680	23	% (1,236)	-46
Total other income (expense), net	(6,963 )	-55	% 296	2	% (7,259)	-2452
Loss before income taxes	(41,929)	-329	% (33,593)	-283	% (8,336)	25
Provision for income taxes	—	—	—	—	—	—
Net loss	\$(41,929)	-329	% \$(33,593)	-283	% \$(8,336)	25

## Revenue

Total revenue for the six month period ended September 30, 2017 increased by 7% to \$12.7 million, compared with \$11.9 million for the six month period ended September 30, 2016. Product sales revenue increased 15% to \$12.1 million for the six month period ended September 30, 2017, compared with \$10.6 million for the six month period ended September 30, 2016. The increase in product sales was primarily attributable to growth in product sales to OEM customers and incremental direct sales of conventional reagent products to customers in the United States. Products sold by standing purchase order were 74% of product sales for the six month period ended September 30, 2017, compared with 75% for the six month period ended September 30, 2016.

The below table sets forth revenue by product group:

	Six months ended September 30, 2017		2016		Change	
	Amount	% of revenue	Amount	% of revenue	Amount	%



Edgar Filing: Quotient Ltd - Form 10-Q

(in thousands, except percentages)

Revenue:								
Product sales - OEM customers	\$8,796	69	%	\$7,358	62	%	\$1,438	20 %
Product sales - direct customers								
and distributors	3,340	26	%	3,203	27	%	137	4 %
Other revenues	600	5	%	1,300	11	%	(700 )	-54%
Total revenue	\$12,736	100	%	\$11,861	100	%	\$875	7 %

OEM Sales. Product sales to OEM customers increased 20% to \$8.8 million for the six month period ended September 30, 2017, compared with \$7.4 million for the six month period ended September 30, 2016. The increase was due to increased sales to existing customers and the impact of recently launched new products.

- 23 -

---

Direct Sales to Customers and Distributors. Direct product sales of \$3.3 million for the six month period ended September 30, 2017 increased by 4% compared with \$3.2 million for the six month period ended September 30, 2016. This mainly consisted of direct sales in the United States which increased to \$2.9 million in the six month period ended September 30, 2017 compared with \$2.8 million in the six month period ended September 30, 2016 as a result of recent product launches and the expansion of our customer base. This increase was offset in part by the fact that there was one fewer red cell shipping cycle to our customers in the United States in the six month period ended September 30, 2017 compared with the six month period ended September 30, 2016.

Other Revenues. Other revenues of \$0.6 million in the six month period ended September 30, 2017 and \$1.3 million in the six month period ended September 30, 2016, consisted of product development fees as the result of the achievement of a product development milestone under the terms of our umbrella supply agreement with Ortho-Clinical Diagnostics Inc., or Ortho. See Note 2 “Summary of Significant Accounting Policies — Revenue Recognition” to our condensed consolidated financial statements included in this Quarterly Report for additional information.

#### Cost of revenue and gross margin

Cost of revenue decreased by 4% to \$5.6 million for the six month period ended September 30, 2017, compared with \$5.9 million for the six month period ended September 30, 2016. Our manufacturing costs are predominantly denominated in pounds sterling and the weakening of the pound versus the dollar accounted for a decrease of \$0.4 million. However, cost of revenue also reflected incremental costs associated with greater sales volumes, which were offset by improved product mix and efficiencies in our manufacturing operations.

Gross profit on total revenue for the six month period ended September 30, 2017 was \$7.1 million, an increase of 18% when compared with \$6.0 million in the six month period ended September 30, 2016. This was attributable to the increase in gross margin on product sales described below offset by a decrease in other revenues of \$0.7 million, which have no corresponding cost.

Gross margin, which represents gross profit expressed as a percentage of total revenue, was 56% for the six month period ended September 30, 2017, compared with 51% for the six month period ended September 30, 2016. Gross margin on product sales, which excludes other revenues, was 54% for the six month period ended September 30, 2017 compared with 45% for the six month period ended September 30, 2016, due to the positive impact of foreign exchange rates, improved product and customer mix and efficiencies at our manufacturing facility in Edinburgh, Scotland.

#### Sales and marketing expenses

Sales and marketing expense was \$3.6 million for the six month period ended September 30, 2017, compared with \$2.5 million for the six month period ended September 30, 2016. As a percentage of total revenue, sales and marketing expenses were 28% for the six month period ended September 30, 2017, compared with 21% for the six month period ended September 30, 2016. The growth in sales and marketing expense in the six month period ended September 30, 2017 was attributable to increased costs of the MosaiQ commercial team, which was established in April 2016.

#### Research and development expenses

Six months ended September 30,

Edgar Filing: Quotient Ltd - Form 10-Q

	2017		2016		Change	
	Amount	% of revenue	Amount	% of revenue	Amount	%
(in thousands, except percentages)						
<b>Research and development expenses:</b>						
MosaiQ research and development	\$25,454	200	% \$25,451	215	% \$3	0 %
Other research and development	696	5	% 1,004	8	% (308)	-31 %
Tax credits and grants	(136 )	-1	% (159 )	-1	% 23	-14 %
<b>Total research and development expenses</b>	<b>\$26,014</b>	<b>204</b>	<b>% \$26,296</b>	<b>222</b>	<b>% \$(282)</b>	<b>-1 %</b>

Research and development expenses decreased by 1% to \$26.0 million for the six month ended September 30, 2017, compared with \$26.3 million for the six month period ended September 30, 2016. As a percentage of total revenue, research and development expenses decreased to 204% for the six month period ended September 30, 2017, compared with 222% for the six month period ended September 30, 2016. Our MosaiQ research and development expenditures were the same for the six month period ended September 30, 2017 as they were for the six month period ended September 30, 2016, but our other research and development expenditures in our reagents business were reduced as a result of the different nature of the projects underway.

### General and administrative expenses

General and administrative expenses increased by 13% to \$12.5 million for the six month period ended September 30, 2017, compared with \$11.1 million for the six month period ended September 30, 2016. \$0.5 million of the increase was due to increased stock compensation expense: we recognized \$2.5 million of stock compensation expense in the six month period ended September 30, 2017 compared with \$2.0 million in the six month period ended September 30, 2016. Stock compensation expense is recognized over the expected vesting period of incentive awards and the increase was mainly due to the compensation expense on awards granted since May 31, 2016, many of which have vesting terms that are conditional upon the achievement of MosaiQ development targets. In addition, in the six month period ended September 30, 2017, there were greater personnel-related costs as we move towards commercialization of MosaiQ and the relocation of our manufacturing facility in Scotland. As a percentage of total revenue, general and administrative expenses increased to 98% for the six month period ended September 30, 2017, compared with 93% for the six month period ended September 30, 2016.

### Other income (expense)

Net interest expense was \$8.4 million for the six month period ended September 30, 2017, compared with \$2.4 million for the six month period ended September 30, 2016. Interest expense in the six month period ended September 30, 2017 included \$5.0 million of interest charges on our Secured Notes. Interest expense in the six month period ended September 30, 2016 included interest charges of \$1.3 million on our borrowings of \$30 million from MidCap Financial Trust (or MidCap), which bore interest at LIBOR plus 6.7% (with a LIBOR floor of 2.00%). Interest expense in the six month periods ended September 30, 2017 and September 30, 2016 included amortization of deferred debt issue costs of \$2.9 million and \$0.5 million, respectively. In the six month period ended September 30, 2017, this included amortization of the expected costs of the royalty rights agreements entered into in October 2016 in connection with the issuance of the Secured Notes. Net interest expense also included \$0.5 million of dividends accrued on the 7% cumulative redeemable preference shares in each of the six month periods ended September 30, 2017 and September 30, 2016.

Other income for the six month periods ended September 30, 2017 and September 30, 2016 included \$1.4 million and \$2.7 million, respectively, of foreign exchange gains arising on monetary assets and liabilities denominated in foreign currencies.

### Quarterly Results of Operations

Our quarterly product sales can fluctuate depending upon the shipment cycles for our red blood cell-based products, which account for approximately three-quarters of our current product sales. For our sales of these products in Europe, we typically experience 13 shipping cycles per year. This equates to three shipments of each product per quarter, except for one quarter per year when four shipments occur. For our sales of these products in the United States, we ship on a two-week cycle, which also results in different numbers of shipments between quarters. In fiscal 2016, the greatest impact of extra product shipments occurred in our first quarter and the greatest impact thus far in fiscal 2017 has also occurred in the first quarter, although to a slightly lesser extent than in fiscal 2016. The timing of shipment of bulk antisera products to our OEM customers may also impact revenues from quarter to quarter. We also experience some seasonality in demand around holiday periods in both Europe and the United States. As a result of these factors, we expect to continue to see seasonality and quarter-to-quarter variations in our product sales. The timing of product development fees included in other revenues is mostly dependent upon the achievement of pre-negotiated project or revenue milestones.

### Liquidity and Capital Resources

Since our commencement of operations in 2007, we have incurred net losses and negative cash flows from operations. As of September 30, 2017, we had an accumulated deficit of \$235.2 million. During the six month period ended September 30, 2017, we incurred a net loss of \$41.9 million and used \$32.7 million of cash in operating activities. As described under results of operations, our use of cash during the six month period ended September 30, 2017 was primarily attributable to our investment in the development of MosaiQ and corporate costs, including costs related to being a public company.

From our incorporation in 2012 to March 31, 2017, we have raised \$70.6 million of gross proceeds through the private placement of our ordinary and preference shares and warrants, \$132.8 million of gross proceeds from public offerings of our shares and warrants and \$84.0 million of gross proceeds from the issuance of the Secured Notes. On April 10, 2017, we completed a public offering of 8,050,000 newly issued ordinary shares at a price of \$6.00 per share which raised \$48.3 million of gross proceeds before underwriting discounts and other offering expenses. As of September 30, 2017, we had cash and cash equivalents and short-term investments of \$24.9 million, including \$5.4 million of cash held in restricted accounts as part of the arrangements relating to our Secured Notes and the lease of our property in Eysins, Switzerland.

On October 24, 2017, we entered into subscription agreements for the private placement of (i) 7,874,683 newly issued ordinary shares at a subscription price of \$4.64 per share, (ii) newly issued warrants, at a purchase price of \$0.125 per underlying warrant share, exercisable for up to 8,414,683 ordinary shares at an exercise price of \$5.80 per ordinary share, and (iii) newly issued pre-funded

warrants at a purchase price of \$4.755 per underlying pre-funded warrant share, exercisable for up to 550,000 ordinary shares at an exercise price of \$0.01 per ordinary share. The aggregate gross proceeds were \$40.2 million. If the warrants are exercised in full prior to their expiration on July 31, 2018, it would result in additional proceeds of \$48.8 million. However, there can be no assurance that the warrants will be exercised.

#### Cash Flows for the Six Month Periods Ended September 30, 2017 and 2016

##### Operating activities

Net cash used in operating activities was \$32.6 million during the six month period ended September 30, 2017, which included net losses of \$41.9 million offset by non-cash items of \$11.1 million. Non-cash items were depreciation and amortization expense of \$5.1 million, share-based compensation expense of \$2.5 million, Swiss pension costs of \$0.3 million, amortization of deferred debt issue costs of \$2.9 million and accrued preference share dividends of \$0.5 million, offset by amortization of lease incentives of \$0.2 million. We also experienced a net cash outflow of \$1.7 million from changes in operating assets and liabilities during the period, consisting of a \$1.1 million increase in inventories, a \$0.5 million reduction in accounts payable and accrued liabilities and a \$0.6 million reduction in accrued compensation and benefits offset by a \$0.2 million decrease in accounts receivable and a \$0.2 million decrease in other assets.

Net cash used in operating activities was \$29.0 million during the six month period ended September 30, 2016, which included net losses of \$33.6 million offset by non-cash items of \$7.8 million. Non-cash items were depreciation and amortization expense of \$4.6 million, share-based compensation expense of \$2.0 million, Swiss pension costs of \$0.3 million, amortization of deferred debt issue costs of \$0.5 million and accrued preference share dividends of \$0.5 million, offset by amortization of lease incentives of \$0.2 million. We also experienced a net cash outflow of \$3.2 million from changes in operating assets and liabilities during the period, consisting of a \$1.9 million increase in accounts receivable, a \$1.3 million increase in inventories and a \$1.6 million increase in other assets, offset by a \$1.6 million increase in accounts payable and accrued liabilities.

##### Investing activities

Net cash used in investing activities was \$6.9 million for the six month period ended September 30, 2017 and \$9.5 million for the six month period ended September 30, 2016. We spent \$12.3 million on purchases of property and equipment in the six month period ended September 30, 2017 which was mainly related to the construction of a new manufacturing facility for our conventional reagents business, and we realized \$5.4 million of net cash inflows from our investments in short-term money market funds in the six month period ended September 30, 2017. Purchases of property and equipment in the six month period ended September 30, 2016 were \$9.4 million and included \$1.9 million related to the MosaiQ project and \$7.4 million related to our conventional reagent business.

##### Financing activities

Net cash provided by financing activities was \$45.2 million during the six month period ended September 30, 2017, consisting of \$45.3 million of net proceeds from the issuance of ordinary shares and exercise of share options offset by repayments on finance leases. Net cash provided by financing activities was \$16.3 million during the six month period ended September 30, 2016, consisting of \$16.4 million of net proceeds from the issuance of ordinary shares offset by \$0.1 million of repayments on finance leases.

##### Operating and Capital Expenditure Requirements

We have not achieved profitability on an annual basis since we commenced operations in 2007 and we expect to incur net losses for at least the next fiscal year. As we move towards the commercial launch of MosaiQ, we expect our operating expenses during the year ended March 31, 2018 to be similar to those of the year ended March 31, 2017, as we continue to invest in growing our customer base, expanding our marketing and distribution channels, hiring additional employees and investing in other product development opportunities while our development expenditures on MosaiQ decrease.

As of September 30, 2017, we had cash and cash equivalents and short-term investments of \$19.8 million, including \$0.3 million of cash held in a restricted account as part of the arrangements relating to the lease of our property in Eysins, Switzerland. We also held \$5.0 million in a cash reserve account maintained with the collateral agent for the Secured Notes.

Our future capital requirements will depend on many factors, including:

- our progress in developing and commercializing MosaiQ and the cost required to complete development, obtain regulatory approvals and complete our manufacturing scale up;
- Ortho's progress in commercializing MosaiQ for the patient testing market;

- 26 -

---

- our ability to manufacture and sell our conventional reagent products, including the costs and timing of further expansion of our sales and marketing efforts;
- our ability to collect our accounts receivable;
- our ability to generate cash from operations;
- any acquisition of businesses or technologies that we may undertake; and
- our ability to penetrate our existing market and new markets.

We expect to fund our operations in the near-term, including the continued development of MosaiQ through successful field trial completion to commercialization, from a combination of funding sources, including through the use of existing cash and short-term investment balances, the issuance of new equity, debt or other securities, milestone payments under our distribution and supply agreement with Ortho and the sale and leaseback of our Biocampus facility in Edinburgh, Scotland. We are confident in the availability of these funding sources. However, there can be no assurance that we will be able to obtain adequate financing when necessary and the terms of any financings may not be advantageous to us and may result in dilution to our shareholders. In particular, we will receive additional proceeds if the warrants we issued in our October 2017 private placement are exercised. However, there can be no assurance that the warrants will be exercised.

#### Contractual Obligations

Our contractual obligations and commitments were summarized in our Annual Report on Form 10-K for the year ended March 31, 2017.

There were no major changes in the nature of our contractual obligations and commitments between March 31, 2017 and September 30, 2017.

#### Critical Accounting Policies and Significant Judgments and Estimates

We have prepared our condensed consolidated financial statements in accordance with U.S. GAAP. Our preparation of these condensed consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, expenses and related disclosures at the date of the consolidated financial statements, as well as revenue and expenses during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from these estimates under different assumptions or conditions.

While our significant accounting policies are described in more detail in Note 2 to our condensed consolidated financial statements included in this Quarterly Report, we believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our financial statements.

#### Revenue recognition and accounts receivable

Revenue is recognized in accordance with Accounting Standards Codification, or ASC, Topic No. 605, "Revenue Recognition," when the following four basic criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services are rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. For product sales, the application of this policy results in sales revenue being recorded at the point of delivery of product to the customer.

We also earn revenue from the provision of development services to a small number of OEM customers. These development service contracts are reviewed individually to ensure that our revenue recognition is in accordance with



applicable accounting standards, including ASC Topic No. 605. In recent years, our product development revenues have been commensurate with achieving milestones specified in the respective development agreements relating to those products. These milestones may include the approval of new products by the European or U.S. regulatory authorities, which are not within our control. While there can be no assurance that we will earn product development revenues when milestones are achieved, the nature of the milestones have been such that they effectively represent full completion of a particular part of a development program. As a result, we typically fully recognize milestone-related revenues as the milestones are achieved in accordance with applicable accounting standards.

Under certain development contracts, we also manufacture and supply the customer with finished products once it has been approved for use by relevant regulatory agencies. These agreements reflect both arrangements for product development and the sales prices and

- 27 -

---

other contractual terms for subsequent supply of the product to the customer. Under these development contracts, we view the development service revenue as distinct from subsequent product sales revenue, and we recognize each separately as described above.

Accounts receivable consist primarily of amounts due from OEM customers, hospitals, donor testing laboratories, and distributors. Accounts receivable are reported net of an allowance for uncollectible accounts, which we also refer to as doubtful accounts. The allowance for doubtful accounts represents a reserve for estimated losses resulting from our inability to collect amounts due from our customers. Direct sales, where we may make many low value sales to a large number of customers, represents a larger risk of doubtful accounts, as opposed to OEM customer sales consisting primarily of a small number of well established businesses with whom we have a long trading history. The collectability of our trade receivables balances is regularly evaluated based on a combination of factors such as the ageing profile of our receivables, past history with our customers, changes in customer payment patterns, customer credit-worthiness and any other relevant factors. Based on these assessments, we adjust the reserve for doubtful accounts recorded in our financial statements.

#### Inventories

We record inventories at the lower of cost (first-in, first-out basis) or market (net realizable value), net of reserves. We record adjustments to inventory based upon historic usage, expected future demand and shelf life of the products held in inventory. We also calculate our inventory value based on the standard cost of each product. This approach requires us to analyze variances arising in the production process to determine whether they reflect part of the normal cost of production, and should therefore be reflected as inventory value, or whether they are a period cost and should thus not be included in inventory.

#### Intangible assets

The intangible assets included in our financial statements include intangible assets identified as at the time of the acquisition of the business of Alba Bioscience on August 31, 2007. At the time of this acquisition, we identified intangible assets related to customer relationships, master cell lines and certain other items, which include domain names and product trademarks. The customer relationships have been amortized over a five-year period, which resulted in them becoming fully amortized at August 31, 2012. The other items were amortized over a seven-year period from August 31, 2007, which resulted in them becoming fully amortized at August 31, 2014.

The intangible assets related to master cell lines reflect the know-how and market recognition associated with the cell lines, which are used as the source material of certain of our products. These cell lines are maintained by us and have an indefinite life. We have nevertheless decided to amortize the intangible assets over a forty-year period to reflect the possibility of market changes or other events resulting in the lines becoming technically obsolete at some future date. In the event that any of the lines cease to be used, we would record additional amortization at that point.

We also include in intangible assets the costs of obtaining product licenses for our products. These include external costs such as regulatory agency fees associated with the approval and bringing to market of our products once the development is complete. We amortize these over an expected product life of ten years, although if any such product ceased to be produced, we would record additional amortization at that point.

#### Income taxes

We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of our assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing

NOLs and research and development credit carry forwards. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.

We follow the accounting guidance for uncertainties in income taxes, which prescribes a recognition threshold and measurement process for recording uncertain tax positions taken, or expected to be taken, in a tax return in the financial statements. Additionally, the guidance also prescribes the derecognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. We accrue for the estimated amount of taxes for uncertain tax positions if it is more likely than not that we would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained. We did not have any accrued interest or penalties associated with any unrecognized tax positions, and there were no such interest or penalties recognized during the six month period ended September 30, 2017 or the years ended March 31, 2017, 2016 or 2015.

- 28 -

---

### Stock compensation expense

Stock compensation expense is measured at the grant date based on the fair value of the award and is recognized as an expense in the income statement over the vesting period of the award. The calculation of the stock compensation expense is sensitive to the fair value of the underlying ordinary shares. The fair value of option awards and multi-year performance based restricted share units or MRSUs at the grant date is calculated using the Black-Scholes model or other valuation models, which use a number of assumptions to determine the fair value. Details of the assumptions used are set out in the notes to the condensed consolidated financial statements included in this Quarterly Report.

### Defined Benefit Pension Obligations

We account for the pension obligations of our Swiss subsidiary as a defined benefit plans under Accounting Standards Codification Topic, 715 Compensation – Retirement Benefits or ASC 715. This requires that an actuarial valuation be performed to determine the funded status of the pension arrangements. The actuarial valuation is based on a number of assumptions, details of which are set out in the notes to the audited consolidated financial statements included in our March 31, 2017 Annual Report on Form 10-K.

### Royalty Liability

The royalty rights agreements entered into in connection with the issue of our Secured Notes are treated as sales of future revenues that meet the requirements of Accounting Standards Codification Topic 470 “Debt” to be treated as debt. The estimated future cash outflows under the royalty rights agreements have been combined with the Secured Notes issuance costs and interest payable to calculate the effective interest rate of the Secured Notes and will be expensed through interest expenses using the effective interest rate method over the term of the Secured Notes and royalty rights agreements. Estimating the future cash outflows under the royalty rights agreements requires us to make certain estimates and assumptions about future sales of MosaiQ products. These estimates of the magnitude and timing of MosaiQ sales are subject to significant variability due to the current status of development of MosaiQ products, and thus are subject to significant uncertainty. Therefore, the estimates are likely to change as we gain experience of marketing MosaiQ, which may result in future adjustments to the accretion of the interest expense and the amortized cost based carrying value of the Secured Notes.

### Off-Balance Sheet Arrangements

We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or for any other contractually narrow or limited purpose.

### Recent Accounting Pronouncements

The FASB issued ASU 2014-09, Revenue from Contracts with Customers that will supersede virtually all revenue recognition guidance in GAAP. The new standard provides accounting guidance for all revenue arising from contracts with customers and affects all entities that enter into contracts to provide goods or services to their customers (unless the contracts are in the scope of other GAAP requirements). The guidance also provides a model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets, such as property and equipment, including real estate. The new standard is effective for public entities for fiscal years beginning after December 15, 2017 and for interim periods therein. We have undertaken an initial assessment of the impact that adoption of this standard will have on future financial statements and we do not believe that it will have any significant effect on our revenue recognized to date.

The FASB issued ASU 2016-02, Leases that requires lessees to recognize a right-of-use asset and a lease liability on their balance sheets but recognize expenses on their income statements in a manner similar to current accounting standards. ASU 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. The standard could have significant implications for the accounting for our operating leases. The new standard will not be mandatory until our fiscal year ending March 31, 2020 and we are currently considering its implications.

#### JOBS Act

Under the Jumpstart Our Business Startups Act of 2012, emerging growth companies that become public can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

### Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risks in the ordinary course of our business. These market risks are principally limited to interest rate fluctuations and foreign currency exchange rate fluctuations.

#### Interest rate sensitivity

We are exposed to market risk related to changes in interest rates as it impacts our interest income and expense.

Cash, cash equivalents and cash reserve account. At September 30, 2017, we had cash and cash equivalents of \$9.1 million and we also held \$5.0 million in a cash reserve account maintained with the collateral agent for the Secured Notes. Our exposure to market risk includes interest income sensitivity, which is impacted by changes in the general level of U.S. and European interest rates. Our cash and cash equivalents and the cash reserve account are held in interest-bearing savings accounts and bank accounts. We do not enter into investments for trading or speculative purposes. Due to the current levels of interest rates, we do not believe an immediate one percentage point change in interest rates would have a material effect on the fair market value of our holdings, and therefore we do not expect our operating results or cash flows to be significantly affected by changes in market interest rates.

Senior secured notes. At September 30, 2017, we had term debt of \$84.0 million outstanding under the Secured Notes. The Secured Notes are fixed-rate instruments and, as a result, a change in market interest rates has no impact on our interest expense incurred or cash flows.

#### Foreign currency exchange risk

The main currencies that we use for our trading operations are the U.S. Dollar, the Pound Sterling, the Swiss Franc and to a lesser extent, the Euro. Our meaningful cash balances are held in a mixture of U.S. Dollars, Euros, Pounds Sterling and Swiss Francs. These cash balances may not be the same as the functional currencies of the Quotient entities in which they are held and as a result, exchange rate fluctuations may result in foreign exchange gains and losses on our income statement.

We are subject to market risks arising from changes in foreign currency exchange rates between the U.S. Dollar and the Pound Sterling and the U.S. Dollar and the Swiss Franc. Accordingly, fluctuations in the U.S. Dollar versus Pounds Sterling and U.S. Dollar versus the Swiss Franc exchange rate give rise to exchange gains and losses. These gains and losses arise from the conversion of U.S. Dollars and Euros to Pounds Sterling and the retranslation of cash, accounts receivable, intercompany indebtedness and other asset and liability balances. Based on our assets and liabilities held in Pounds Sterling at September 30, 2017, we estimate that a 5% strengthening of the Pound Sterling against the U.S. Dollar would give rise to a gain of approximately \$1.1 million and a 5% weakening of the Pound Sterling against the U.S. Dollar would give rise to loss of approximately \$1.1 million. Based on our assets and liabilities held in Swiss Francs at June 30, 2017, we estimate that a 5% strengthening of the Swiss Franc against the U.S. Dollar would give rise to a gain of approximately \$1.9 million and a 5% weakening of the Swiss Franc against the U.S. Dollar would give rise to loss of approximately \$1.9 million.

Most of our revenues are earned in U.S. Dollars, but the costs of our conventional reagent manufacturing operations are payable mainly in Pounds Sterling. We therefore closely monitor the results of our UK operations to address this difference. During the year ended March 31, 2017, the net operating expenses arising in Pounds Sterling from our UK conventional reagent manufacturing operations amounted to \$16.3 million. This expenditure was offset by revenues arising in U.S. Dollars and other currencies. We have entered into forward contracts to hedge against the effects of

fluctuations in the U.S. Dollar versus the Pounds Sterling exchange rate. The principal value of the hedges related to the results of fiscal year 2018 is \$6.0 million and, based on this, a hypothetical instantaneous 5% strengthening of the Pound Sterling against the U.S. Dollar would reduce our net income by \$0.5 million in the year ending March 31, 2018 after taking account of the shelter provided by our existing hedging arrangements through March 31, 2018. Similarly, a hypothetical instantaneous 5% weakening of the Pound Sterling against the U.S. Dollar would increase group net income by \$0.5 million over the same period.

We do not use financial instruments for trading or other speculative purposes.

Our management does not believe that inflation in past years has had a significant impact on our results from operations. In the event inflation affects our costs in the future, we will offset the effect of inflation and maintain appropriate margins through increased selling prices.

#### Item 4. Controls and Procedures

##### Evaluation of disclosure controls and procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2017, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms, and is accumulated and communicated to our management, including our Chief Executive and Chief Financial Officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

##### Changes in internal control over financial reporting

There were no material changes to our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## PART II – OTHER INFORMATION

#### Item 1. Legal Proceedings

We are not currently a party to any pending legal proceedings that we believe could have a material adverse effect on our business or financial condition. However, we may be subject to various claims and legal actions arising in the ordinary course of business from time to time.

#### Item 1A. Risk Factors

There have been no material changes in the risk factors described in Item 1A "Risk Factors" of our Annual Report on Form 10-K for the year ended March 31, 2017.

#### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

##### Unregistered Sales of Equity Securities

None.

#### Item 3. Defaults Upon Senior Securities

None.



Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

The following is a list of exhibits filed as part of this Quarterly Report on Form 10-Q:

- 31 -

---

Exhibit No. Description

- 10.1 Form of Change of Control Agreement dated as of August 7, 2017 between the Company and the following executive officers: Paul Cowan, Christopher Lindop, Edward Farrell, Jeremy Stackawitz and Roland Boyd (filed as Exhibit 10.1 to our report on Form 8-K filed on August 10, 2017 and incorporated herein by reference)
- 31.1 Certification of Paul Cowan, Chairman and Chief Executive pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 31.2 Certification of Christopher Lindop, Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.1 Certification of Paul Cowan, Chairman and Chief Executive pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 32.2 Certification of Christopher Lindop, Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 101\* The following financial statements from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets (unaudited), (ii) Condensed Consolidated Statements of Comprehensive Loss (unaudited), (iii) Condensed Consolidated Statements of Redeemable Convertible Preference Shares and Changes in Shareholders' Deficit (unaudited), (iv) Condensed Consolidated Statements of Cash Flows (unaudited) and (v) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text and including detailed tags.

\* XBRL information is furnished and not filed for purposes of Section 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement, prospectus or other document to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

QUOTIENT LIMITED

Date: October 31, 2017 /s/ Paul Cowan  
Paul Cowan

Chief Executive Officer and  
Chairman of the Board of Directors

- 33 -